Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants With Advanced Solid Tumors

NCT06792552 is registered in ClinicalTrials.gov with NextCure, Inc. as lead sponsor.

NCT NCT06792552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06792552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants With Advanced Solid Tumors
Lead sponsor
NextCure, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 26, 2025
Completion date
August 31, 2028
Enrollment
738 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, fallopian tube cancer, nsclc (non-small cell lung cancer), papillary renal cell carcinoma (prcc), platinum resistant ovarian cancer, primary peritoneal cancer, renal cell carcinoma (rcc), uterine serous carcinoma (usc)